Pierre Major

9.2k total citations · 1 hit paper
154 papers, 6.4k citations indexed

About

Pierre Major is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pierre Major has authored 154 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 47 papers in Molecular Biology and 47 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pierre Major's work include Bone health and treatments (45 papers), Radiopharmaceutical Chemistry and Applications (30 papers) and Prostate Cancer Treatment and Research (26 papers). Pierre Major is often cited by papers focused on Bone health and treatments (45 papers), Radiopharmaceutical Chemistry and Applications (30 papers) and Prostate Cancer Treatment and Research (26 papers). Pierre Major collaborates with scholars based in Canada, United States and United Kingdom. Pierre Major's co-authors include Donald Küfe, Richard J. Cook, Allan Lipton, Robert E. Coleman, E.Michael Egan, Matthew Smith, John J. Seaman, Janet E. Brown, G. Peter Beardsley and Fred Saad and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Pierre Major

152 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials

2001 520 citations Pierre Major et al. profile →

Peers

Countries citing papers authored by Pierre Major

Since Specialization

Citations

This map shows the geographic impact of Pierre Major's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Major with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Major more than expected).

Fields of papers citing papers by Pierre Major

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Major. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Major. The network helps show where Pierre Major may publish in the future.

Co-authorship network of co-authors of Pierre Major

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Major. A scholar is included among the top collaborators of Pierre Major based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Major. Pierre Major is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy 2025 ·International Journal of Radiation OncologyBiologyPhysics ·Himu Lukka, Stephanie L. Pugh, William U. Shipley, Pierre Major, Oliver Sartor, Ian S. Dayes, Jean-Paul Bahary, Jason A. Efstathiou, Thomas M. Pisansky, Kenneth L. Zeitzer, C.A. Lawton, Robert T. Dess, (unknown), Alexander G. Balogh, Luís Souhami, Seth A. Rosenthal, (unknown), Wendy Seiferheld, Felix Y. Feng, Howard M. Sandler	1
2	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity 2023 ·Journal of Experimental & Clinical Cancer Research ·Yan Gu, Xiaozeng Lin, Ying Dong, Geoffrey A. Wood, Nabil G. Seidah, Geoff H. Werstuck, Pierre Major, Michael Bonert, Anil Kapoor, Damu Tang	25
3	AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma 2022 ·Biomedicines ·Ashley A. Stegelmeier, Lisa A. Santry, (unknown), Kathy Matuszewska, (unknown), (unknown), (unknown), Sylvia P. Thomas, (unknown), (unknown), Yanlong Pei, (unknown), Jacob P. van Vloten, (unknown), Brad Thompson, Pierre Major, Jim Petrik, Byram W. Bridle, Sarah K. Wootton	6
4	Pathologist workload, work distribution and significant absences or departures at a regional hospital laboratory 2022 ·PLoS ONE ·Michael Bonert, Uzma Zafar, Raymond Maung, (unknown), Asghar Naqvi, Christian Finley, Jean‐Claude Cutz, Pierre Major, Anil Kapoor	7
5	Tumour vasculature: Friend or foe of oncolytic viruses? 2020 ·Cytokine & Growth Factor Reviews ·Lisa A. Santry, Jacob P. van Vloten, (unknown), Kathy Matuszewska, (unknown), (unknown), (unknown), Ashley A. Stegelmeier, Pierre Major, Sarah K. Wootton, Jim Petrik, Byram W. Bridle	22
6	Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer 2018 ·Clinical Cancer Research ·Kathy Matuszewska, Lisa A. Santry, Jacob P. van Vloten, (unknown), Pierre Major, Jack Lawler, Sarah K. Wootton, Byram W. Bridle, Jim Petrik	60
7	Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development 2018 ·Translational Oncology ·Yan Gu, (unknown), Anil Kapoor, Wenjuan Mei, Yanzhi Jiang, Judy Yan, Jason De Melo, (unknown), Huixiang Yang, Jean‐Claude Cutz, Michael Bonert, Pierre Major, Damu Tang	20
8	Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer 2017 ·Molecular Therapy — Methods & Clinical Development ·Lisa A. Santry, (unknown), Leonardo Susta, Geoffrey A. Wood, Pierre Major, Jim Petrik, Byram W. Bridle, Sarah K. Wootton	31
9	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer 2016 ·Cancer Research ·Judy Yan, Diane Ojo, Anil Kapoor, Xiaozeng Lin, Jehonathan H. Pinthus, Tariq Aziz, Tarek A. Bismar, Fengxiang Wei, Nicholas Wong, Jason De Melo, Jean‐Claude Cutz, Pierre Major, Geoffrey A. Wood, Hao Peng, Damu Tang	40
10	BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation 2014 ·Oncogene ·Fengxiang Wei, Diane Ojo, Xuelei Lin, Nicholas Wong, Lizhi He, Judy Yan, (unknown), Pierre Major, Duozhuang Tang	28
11	SIPL1-facilitated PTEN ubiquitination contributes to its association with PTEN 2014 ·Cellular Signalling ·Jason De Melo, Xiaozeng Lin, Lizhi He, Fengxiang Wei, Pierre Major, Damu Tang	17
12	A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer 2011 ·Investigational New Drugs ·Daniel J. Renouf, Patricia A. Tang, Pierre Major, Monika K. Krzyzanowska, (unknown), John R. Goffin, David W. Hedley, Lisa Wang, (unknown), Malcolm J. Moore	21
13	Effect of bisphosphonates on pain and quality of life in patients with bone metastases 2009 ·Nature Reviews Clinical Oncology ·Luís Costa, Pierre Major	137
14	Hypoxia-Induced Lactate Dehydrogenase Expression and Tumor Angiogenesis 2007 ·Clinical Colorectal Cancer ·Stephen Colgan, Som D. Mukherjee, Pierre Major	35
15	A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS 2006 ·Annals of Oncology ·Tanja Trarbach, Pierre Major, Heinz‐Josef Lenz, DJ Kerr, Kelly Pendergrass, Jean‐Yves Douillard, (unknown), Amanda Littlewood‐Evans, Laurent Dembélé, Christian Jacques, Eric Van Cutsem	2
16	Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors 2005 ·JNCI Journal of the National Cancer Institute ·J. E. Brown, Richard J. Cook, Pierre Major, Allan Lipton, (unknown), Matthew Smith, Ker‐Ai Lee, Ming Zheng, Y. Hei, Robert E. Coleman	432
17	A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer 2005 ·Investigational New Drugs ·Mary J. MacKenzie, Holger W. Hirte, (unknown), (unknown), Rakesh Goel, Pierre Major, Wilson H. Miller, Lawrence Panasci, Ian A.J. Lorimer, Gerald Batist, S. Matthews, (unknown), Lesley Seymour	56
18	Quantitative dot blot analyses of blood‐group‐related antigens in paired normal and malignant human breast tissues 1992 ·International Journal of Cancer ·(unknown), Arnold S. Dion, Charlene J. Williams, (unknown), (unknown), (unknown), Meenhard Herlyn, Pierre Major	29
19	Enhanced Expression and Secretion of an Epithelial Membrane Antigen (MA5) in a Human Mucinous Breast Tumor Line (BT549) 1990 ·Tumor Biology ·Charlene J. Williams, Pierre Major, Arnold S. Dion	6
20	Related Glycoproteins from Normal Secretory and Malignant Breast Cells 1989 ·Tumor Biology ·(unknown), Pierre Major, (unknown), Arnold S. Dion	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact